Biopharmaceutical company MetVital Inc said on Tuesday that it will proceed with its clinical investigation of 'Anhydrous Enol-Oxaloacetate' (AEO) as a potential treatment for patients with Glioblastoma Multiforme following the US Food and Drug Administration (FDA) approval.
Glioblastoma Multiforme is reportedly the most aggressive of the gliomas. It is often referred to as a grade IV astrocytoma and is the most common type of brain cancer.
The US FDA notice follows the submission of the company's investigational new drug (IND) application for the Phase 2A 'Proof of Concept' trial.
AEO is a patented metabolite and is the company's lead clinical development candidate for Glioblastoma Multiforme. The measured endpoints in the trial include Overall Survival (OS), Progression Free Survival at six months (PFS-6) as well as Seizure amelioration.
According to the company, the Anhydrous Enol-Oxaloacetate is a metabolite that has demonstrated efficacy in animal models with human Glioblastoma Multiforme tissue implants, in animal models of ALS, and in animal models of Alzheimer's disease. The US FDA Orphan Drug Designations for oxaloacetate have been received for Gliomas, ALS and Hepatocellular Carcinoma.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML